AUG 19 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 10/727,399

Customer No.: 23379

Applicant: Lou et al.

Confirmation No.: 7526

Filed: Dec 03, 2003

Group Art Unit: 1632

Docket No.: S03-250

Title: Somatic Recombination

Examiner: Woitach, Josheph T. CERTIFICATE OF TRANSMISSION

I hereby certify that this corr is being transmitted by facsimile to the Comm for Patents 571-273-8300 on August

19, 2006

Signed

Richard Aron Osman

RESPONSE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Commissioner:

Thank you for the Restriction Requirement dated Aug 14, 2006.

We elect Group L claims 1-7.

For "Species 1. the marker gene (claims 3-5)" we elect: wherein the first and second markers are fluorescent proteins selected from the group consisting of GFP and RFP (claim 3).

For "Species 2: regulator for the expression of the transposase" we note that no "transposase" is recited in our claims. To the extent "recombinase" is intended we elect "wherein functional expression of the recombinase is temporally restricted by administration of a drug selected from the group consisting of tamoxifen and doxycycline" (claim 7).

The Examiner is invited to call the undersigned with any suggestions for amending the claims or for further clarification of any of the foregoing. Please charge our Deposit Account No. 19-0750 (order S03-250) any fees, including any necessary extensions of time, relating to this communication.

Respectfully submitted,

SCIENCE & TECHNOLGY LAW GROUP

Richard Aron Osman, J.D., Ph.D., Reg. No. 36,627

Tel: (949) 218-1757; Fax: (949) 218-1767

"To Help Our Customers Get Patents"
Mission Statement, USPTO External Customer Services Guide